Nama's AI scorecard currently rates Clover Health Investments Hold (4.5 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is CLOV's P/E ratio?

Clover Health Investments trades at a trailing price-to-earnings ratio of 40.2.

When does CLOV report earnings?

Clover Health Investments's next scheduled report is on Feb 25, 2027. Analysts expect EPS of -$0.02.

What is the CLOV price target?

The median analyst price target from 5 analysts is $5.50, with a range of $5.00 – $6.00.

Is CLOV Shariah compliant?

Nama's AAOIFI-style screen reads Clover Health Investments as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.

Nama Insights

Clover Health Investments (CLOV)

Healthcare · Healthcare Plans · NASDAQ

Clover Health Investments (CLOV) is a Healthcare company in the Healthcare Plans industry. It has a market capitalization of $2.57B, a trailing price-to-earnings ratio of 40.2 and a free-cash-flow yield of -2.7%. Over the most recent reported fiscal year, revenue grew 40.3% and free cash flow per share fell 298.3%. Nama's AI scorecard rates it Hold, 4.5 out of 10. On 12-month momentum it ranks in the rising band of its market.

AI scorecard

Hold · 4.5/10

The sections balance. As of Nov 7, 2026.

Momentum

Rising · +74.7% over 12 months ex. last

Second-best fifth of its market on the past year's move.

Shariah screen

Shariah Compliant

Passes our debt, cash and income screen; not a scholar's ruling.

Off its high

-41.0%

How far the last close sits under the highest price of the past five years.

Market cap	$2.57B
Trailing P/E	40.2
Price / book	6.8
Price / sales	1.0
FCF yield	-2.7%
Dividend yield	—
Gross margin	19.8%
Operating margin	-0.2%
Net margin	-0.2%
Revenue growth (YoY)	+40.3%
Revenue growth (3-yr annual)	+20.6%
EPS growth (YoY)	—
FCF/share growth (YoY)	-298.3%
Beta	2.5
Exchange	NASDAQ
Sector	Healthcare
Industry	Healthcare Plans

CLOV earnings

Next report: Feb 25, 2027 (Q4 2026, EPS estimate -$0.02). Beat the EPS estimate in 2 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Nov 3, 2026	$0.03	$0.01	+200.0%	—
Q2 2026	Aug 5, 2026	$0.07	$0.05	+40.0%	$743.17M
Q1 2026	May 6, 2026	$0.07	$0.07	+0.0%	$749.19M
Q4 2025	Feb 25, 2026	-$0.05	-$0.05	+0.0%	$487.71M

CLOV analyst price target

Median target $5.50 from 5 analysts, ranging $5.00 – $6.00.

Healthcare Plans peers

Ticker	Company	Market cap	P/E
UNH	UnitedHealth Group	$353.17B	19.3
CVS	CVS Health	$107.28B	10.1
ELV	Elevance Health	$91.96B	14.0
CI	Cigna Group	$77.58B	9.3
HUM	Humana	$52.08B	32.7
CNC	Centene	$34.53B	13.2
MOH	Molina Healthcare	$10.87B	104.5
OSCR	Oscar Health	$9.46B	12.7

Explore live CLOV data on Nama Insights →

CLOV FAQ

Is CLOV a buy?: Nama's AI scorecard currently rates Clover Health Investments Hold (4.5 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is CLOV's P/E ratio?: Clover Health Investments trades at a trailing price-to-earnings ratio of 40.2.
When does CLOV report earnings?: Clover Health Investments's next scheduled report is on Feb 25, 2027. Analysts expect EPS of -$0.02.
What is the CLOV price target?: The median analyst price target from 5 analysts is $5.50, with a range of $5.00 – $6.00.
Is CLOV Shariah compliant?: Nama's AAOIFI-style screen reads Clover Health Investments as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.